Assessment of Memory in Children With Kabuki Syndrom (MEM-K)
Primary Purpose
Kabuki Syndrome
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
No arm intervention
Sponsored by
About this trial
This is an interventional other trial for Kabuki Syndrome focused on measuring Kabuki Syndrome, Intellectual Profile, Memory
Eligibility Criteria
Inclusion Criteria:
- Child from 6 to 16 years old
- Presents an already established diagnosis of Kabuki syndrome.
- Free, informed and written consent signed by the participant's parents, and the investigator (at the latest inclusion day and before any research required by the research).
Exclusion Criteria:
- Be under 6 years old or over 16 years old
- Do not master the French language
- Not having access to language
- Deafness not paired
- Blindness.
Sites / Locations
- Genetic Departement, rare disease, personalized medicine
Outcomes
Primary Outcome Measures
CMS (selective motor control scale) main score
CMS main score
Secondary Outcome Measures
CMS (selective motor control scale) indexes
CMS indexes
Full Information
NCT ID
NCT03547609
First Posted
May 23, 2018
Last Updated
November 30, 2018
Sponsor
University Hospital, Montpellier
1. Study Identification
Unique Protocol Identification Number
NCT03547609
Brief Title
Assessment of Memory in Children With Kabuki Syndrom
Acronym
MEM-K
Official Title
Study on the Mnemic Functioning of Children With Kabuki Syndrome
Study Type
Interventional
2. Study Status
Record Verification Date
May 2018
Overall Recruitment Status
Completed
Study Start Date
June 8, 2018 (Actual)
Primary Completion Date
September 7, 2018 (Actual)
Study Completion Date
September 7, 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Montpellier
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Mnesic function has not, at present, been evaluated in patients with Kabuki Syndrome. Some data from the neuroimagery suggest an impairment of memory function. The objective of our study is to assess the mnesic function of children with Kabuki Syndrom.
Detailed Description
Kabuki Syndrome (SK - OMIM 147920 and 300867 ORPHA: 2322) is a rare genetic disease with a prevalence of approximately 1/32 000 and responsible for a malformation syndrome with mild to moderate intellectual impairment. SK is due to mutations in the KMT2D and KDM6A genes. As part of a national PHRC (AOM 07-090, clinicaltrial NCT01314534, The investigators were able to perform psychometric tests type WISC4 and MRI type VBM). Disability in SK is characterized by a heterogeneous cognitive profile with strengths and weaknesses when calculating IQ. Brain MRI reveals small hippocampi compared to controls. These 2 data are partly contradictory because the strengths of the patients with SK are a working memory and a verbal comprehension index high compared to the other indices of the tests WISC-IV.
The objective of the research is to better understand the mnesic function of children with SK.
25 children aged 6 to 16 will be recruited. The diagnosis of SK will have been authenticated by the demonstration of a mutation in the KMT2D or KDM6A gene.
The memory assessments will be conducted in one visit for each child, who will perform a memory assessment with a neuropsychologist, using the CMS scale.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Kabuki Syndrome
Keywords
Kabuki Syndrome, Intellectual Profile, Memory
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
25 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Other
Intervention Name(s)
No arm intervention
Intervention Description
No arm intervention
Primary Outcome Measure Information:
Title
CMS (selective motor control scale) main score
Description
CMS main score
Time Frame
1 hour
Secondary Outcome Measure Information:
Title
CMS (selective motor control scale) indexes
Description
CMS indexes
Time Frame
1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Child from 6 to 16 years old
Presents an already established diagnosis of Kabuki syndrome.
Free, informed and written consent signed by the participant's parents, and the investigator (at the latest inclusion day and before any research required by the research).
Exclusion Criteria:
Be under 6 years old or over 16 years old
Do not master the French language
Not having access to language
Deafness not paired
Blindness.
Facility Information:
Facility Name
Genetic Departement, rare disease, personalized medicine
City
Montpellier
State/Province
Herault
ZIP/Postal Code
34295
Country
France
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
28295206
Citation
Lehman N, Mazery AC, Visier A, Baumann C, Lachesnais D, Capri Y, Toutain A, Odent S, Mikaty M, Goizet C, Taupiac E, Jacquemont ML, Sanchez E, Schaefer E, Gatinois V, Faivre L, Minot D, Kayirangwa H, Sang KLQ, Boddaert N, Bayard S, Lacombe D, Moutton S, Touitou I, Rio M, Amiel J, Lyonnet S, Sanlaville D, Picot MC, Genevieve D. Molecular, clinical and neuropsychological study in 31 patients with Kabuki syndrome and KMT2D mutations. Clin Genet. 2017 Sep;92(3):298-305. doi: 10.1111/cge.13010. Epub 2017 May 18.
Results Reference
result
Learn more about this trial
Assessment of Memory in Children With Kabuki Syndrom
We'll reach out to this number within 24 hrs